SCHEMBL17801475

SCHEMBL17801475

O=c1cc2ccc(NS(=O)(=O)c3ccc(Br)s3)cc2c[nH]1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.53
KMT2A Q03164 6/20 0.53
LMNA P02545 5/20 0.53
MAPT P10636 4/20 0.53
MAPK1 P28482 3/20 0.53
HTT P42858 8/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
TP53 P04637 2/20 0.52
PKM P14618 2/20 0.52
TSHR P16473 1/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 5/20 0.45
SGK1 O00141 1/20 0.45
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.43
THRB P10828 2/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17801523 0.80 THRB (0.57) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL17808372 0.77 ATIC (0.55) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL5230722 0.69 MAPT (0.69) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL26010796 0.69 LMNA (0.62) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL5780847 0.68 HTR6 (0.59) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL5229199 0.68 MAPT (0.68) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL24254327 0.67 HPGD (0.58) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL9997023 0.67 PFKFB3 (0.57) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL17801496 0.67 ATIC (0.51) MAPTTP53THRB
SCHEMBL1346862 0.66 HTT (0.76) MEN1KMT2ALMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227279-A1 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS Eli Lilly and Company (US) 2017-10-11 EP disclosed
WO-2016089670-A1 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS ELI LILLY AND COMPANY (US) 2016-06-09 WO disclosed